RedHill Biopharma (RDHL) EBIT Margin (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of EBIT Margin data on file, last reported at 2992.87% in Q2 2023.

• On a quarterly basis, EBIT Margin rose 294295.0% year-over-year to 2992.87% in Q2 2023; TTM through Jun 2023 was 122.98%, a 797.0% increase from a year earlier, with the FY2025 full-year figure at 2776.92%, down 269642.0% from the prior year.
• EBIT Margin for Q2 2023 stood at 2992.87%, up from 808.0% in the prior quarter.
• Over the last five years, EBIT Margin for RDHL reached as high as 2992.87% in Q2 2023 and fell as low as 808.0% in Q1 2023.
• Historically, EBIT Margin has averaged 336.14% across 5 years, with a median of 90.03% in 2020.
• Across the five-year window, EBIT Margin tumbled 152314 bps in 2021 and surged 294295 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 739.87% in 2019, then sank by 88 bps to 91.83% in 2020, then slumped by 798 bps to 641.43% in 2021, then increased by 8 bps to 591.81% in 2022, then soared by 606 bps to 2992.87% in 2023.
• Per Business Quant data, the three most recent EBIT Margin figures were 2992.87% in Q2 2023, 808.0% in Q1 2023, and 591.81% in Q4 2022.